object
evalu
efficaci
safeti
caffein
citrat
treatment
apnea
bronchiol
studi
design
elig
infant
age
month
present
main
pediatr
emerg
servic
apnea
associ
bronchiol
stratifi
gestat
age
week
longer
random
receiv
singl
dose
intraven
mgkg
caffein
citrat
salin
placebo
primari
efficaci
outcom
apneafre
period
begin
complet
blind
studi
drug
infus
secondari
outcom
frequenc
apnea
hour
studi
medic
need
noninvasiveinvas
ventil
length
stay
hospit
pediatr
intens
carestepdown
unit
result
total
infant
diagnos
viral
bronchiol
associ
apnea
median
age
day
enrol
rate
respiratori
viru
panel
posit
similar
group
placebo
group
vs
caffein
group
geometr
mean
durat
apneafre
period
hour
ci
hour
caffein
group
hour
ci
hour
placebo
group
p
ci
frequenc
apnea
hour
hour
hour
enrol
need
noninvas
invas
ventil
similar
group
safeti
issu
report
conclus
singl
dose
caffein
citrat
significantli
reduc
apnea
episod
associ
bronchiol
j
pediatr
trial
registr
clinicaltrialsgov
v
iral
bronchiol
common
lower
respiratori
tract
infect
infant
lead
hospit
per
personyear
admit
apnea
bronchiolitisassoci
apnea
subset
apnea
associ
respiratori
virus
appear
mix
central
obstruct
apnea
result
complex
interplay
respiratori
drive
suppress
airway
secret
driven
hyperact
laryngochemoreflex
somnogen
cytokin
case
virusspecif
respiratori
suppress
surfac
protein
caffein
standard
treatment
apnea
prematur
postextub
apnea
preterm
infant
use
amelior
apnea
complic
bronchiol
basi
case
report
observ
studi
caffein
increas
central
respiratori
drive
chemoreceptor
sensit
co
improv
skelet
muscl
contract
reduc
diaphragm
fatigu
lead
better
ventil
increas
metabol
demand
diuresi
tachycardia
dysrhythmia
feed
intoler
reduc
weight
gain
seizur
report
shortterm
side
effect
caffein
although
evid
prospect
studi
caffein
use
treat
apnea
bronchiol
lack
drug
commonli
use
attempt
avoid
intub
consid
standard
care
institut
thu
compar
blind
intraven
caffein
citrat
placebo
shorten
time
resolut
acut
bronchiolitisassoci
apnea
picu
patient
admit
either
area
base
bed
avail
infant
age
month
present
provision
diagnosi
viral
bronchiol
associ
apnea
elig
studi
provision
diagnosi
requir
apnea
preced
prodrom
histori
consist
viral
upper
respiratori
tract
infect
physic
find
bilater
chest
crackl
possibl
associ
cough
rapid
breath
wheez
andor
intercost
retract
outofhospit
apnea
defin
wit
sudden
cessat
breath
associ
cyanosi
hypotonia
within
hour
present
report
caregiv
apnea
pediatr
emerg
center
defin
wit
sudden
cessat
breath
second
prolong
respiratori
paus
associ
cyanosi
bradycardia
observ
medic
staff
bradycardia
defin
heart
rate
beatsminut
patient
exclud
follow
characterist
previou
diagnosi
seizur
disord
gastroesophag
reflux
disord
suspect
sepsi
previou
histori
renal
liver
diseas
known
inborn
error
metabol
congenit
heart
diseas
major
congenit
anomali
upper
lower
respiratori
tract
hypoglycemia
electrolyt
abnorm
present
receipt
caffein
treatment
home
written
inform
consent
sought
parent
legal
guardian
consecut
elig
patient
soon
patient
admit
resuscit
room
shortstay
unit
studi
approv
hospit
institut
review
board
potenti
elig
patient
examin
present
emerg
center
outpati
histori
apnea
admit
infirmaryobserv
unit
patient
observ
apnea
admit
critic
care
area
treatment
patient
assess
studi
elig
within
minut
initi
physician
assess
stabil
enrol
transfer
either
stepdown
unit
picu
base
bed
avail
need
invasivenoninvas
respiratori
support
patient
connect
cardiorespiratori
monitor
philip
healthcar
andov
massachusett
emerg
center
throughout
picustepdown
unit
stay
portabl
cardiorespiratori
monitor
philip
healthcar
transfer
set
alarm
outsid
follow
valu
respiratori
rate
breathsminut
default
apnea
alarm
delay
second
puls
rate
beatsminut
oxygen
satur
caregiv
wait
monitor
alarm
serv
safeti
backup
function
instanc
interven
patient
record
episod
apnea
wit
without
monitor
alarm
requir
immedi
patient
stabil
data
collect
sheet
picustepdown
diari
apnea
record
data
occurr
apnea
collect
patient
record
data
collect
sheet
daili
patient
consent
obtain
underw
plain
chest
radiographi
nasopharyng
swab
rapid
respiratori
viru
panel
capabl
identifi
respiratori
virus
multiplex
realtim
pcr
assay
abi
analyz
thermo
fisher
scientif
waltham
massachusett
random
stratifi
group
patient
born
week
gestat
born
week
gestat
unblind
studi
pharmacist
use
computergener
random
list
prepar
identicallook
number
syring
contain
either
ml
sodium
chlorid
mgkg
caffein
citrat
dilut
make
ml
solut
infus
intraven
syring
pump
minut
inhal
therapi
supplement
oxygen
respiratori
support
hydrat
intervent
provid
discret
treat
physician
patient
venou
blood
ga
analysi
request
treat
physician
sampl
obtain
within
minut
arriv
venou
blood
ga
sampl
obtain
insert
intraven
infus
cannula
limb
freeflow
vein
collect
microtain
tube
ml
sampl
place
ice
immedi
extract
sent
depart
satellit
laboratori
process
within
minut
patient
transfer
picustepdown
unit
ordinari
inpati
pediatr
bed
treat
physician
determin
clinic
stabl
apnea
preced
hour
toler
start
feed
actual
time
transfer
could
delay
owe
lack
bed
avail
primari
efficaci
outcom
time
apneafre
period
begin
complet
blind
studi
drug
infus
express
time
last
apnea
episod
trial
registr
earlier
propos
outcom
length
stay
picu
chang
start
studi
enrol
depend
social
factor
bed
avail
unlik
time
last
apnea
episod
measur
object
patient
major
protocol
violat
receipt
caffein
placebo
group
receipt
second
dose
exclud
proofofconcept
efficaci
trial
secondari
outcom
frequenc
durat
apnea
first
hour
studi
drug
administr
invas
noninvas
respiratori
support
administ
durat
oxygen
therapi
time
feed
toler
length
picustepdown
unit
stay
overal
length
hospit
stay
safeti
measur
spot
heart
rate
compar
everi
hour
enrol
day
estim
sampl
size
perform
retrospect
chart
review
patient
admit
apneaassoci
bronchiol
total
patient
receiv
caffein
identifi
apneafre
hour
admiss
extrapol
result
hour
data
proport
apneafre
hour
enabl
detect
rel
volum
octob
improv
resolut
apnea
power
valu
estim
patient
per
group
requir
compens
dropout
plan
recruit
total
patient
howev
accuraci
estim
compromis
use
dichotom
outcom
calcul
continu
outcom
describ
actual
studi
outcom
report
saw
infant
young
children
visit
bronchiol
age
month
younger
patient
bronchiol
present
apnea
similar
proport
report
current
literatur
estim
would
need
bronchiol
season
complet
trial
enrol
patient
present
bronchiolitisassoci
apnea
categor
continu
data
valu
express
frequenc
percentag
mean
ae
sd
median
iqr
appropri
descript
statist
use
summar
demograph
laboratori
clinic
characterist
patient
kolmogorovsmirnov
test
qq
plot
appropri
use
test
normal
baselin
particip
characterist
treatment
group
caffein
placebo
compar
use
unpair
test
continu
variabl
c
test
categor
variabl
acceler
failur
time
analysi
appli
compar
geometr
mean
time
treatment
group
reach
primari
outcom
apneafre
interv
begin
complet
studi
drug
infus
proport
patient
apnea
resolut
differ
time
point
compar
use
c
test
fisher
exact
test
appropri
quantit
variabl
mean
independ
group
compar
use
unpair
test
mannwhitney
u
test
appropri
depend
result
normal
test
associ
qualit
categor
variabl
assess
use
c
test
fisher
exact
test
appropri
relationship
continu
variabl
examin
use
pearson
correl
coeffici
logrank
test
appli
determin
statist
differ
actual
time
discharg
critic
care
unit
treatment
group
exploratori
subgroup
analysi
primari
secondari
outcom
patient
correct
age
day
caffein
report
prolong
halflif
perform
post
hoc
potenti
risk
factor
apnea
confound
examin
univari
multivari
logist
regress
model
use
apnea
episod
ye
outcom
variabl
birth
weight
respiratori
syncyti
viru
positiveneg
statu
gestat
age
birth
staffobserv
apnea
studi
entri
nonobserv
apnea
studi
entri
apneic
episod
home
posit
pressur
includ
highflow
oxygen
bodi
temperatur
arriv
chest
radiographi
find
venou
blood
ga
analysi
result
obtain
within
minut
arriv
lattermost
variabl
avail
patient
independ
variabl
covari
multivari
regress
model
variabl
consid
statist
signific
p
level
univari
analysi
deem
clinic
import
priori
logist
regress
result
present
along
correspond
ci
test
perform
p
valu
consid
statist
signific
statist
analys
perform
use
spss
ibm
armonk
new
york
data
transfer
spss
packag
stata
se
statacorp
colleg
station
texa
acceler
failur
time
model
analysi
total
infant
assess
enrol
novemb
may
infant
diagnos
viral
bronchiolitisassoci
apnea
median
age
day
iqr
day
enrol
studi
explanatori
proofof
principl
random
trial
rather
pragmat
test
caffein
effect
usual
practic
thu
infant
caffein
group
placebo
group
exclud
analysi
given
extra
dose
caffein
admiss
picu
figur
avail
wwwjpedscom
remain
infant
random
receiv
caffein
citrat
random
receiv
placebo
subject
baselin
characterist
similar
treatment
arm
except
significantli
differ
mean
durat
upper
respiratori
symptom
enrol
caffein
group
ae
day
placebo
group
ae
day
tabl
among
patient
discharg
diagnosi
bronchiol
placebo
group
patient
diagnos
gastroesophag
reflux
diseas
caffein
group
patient
diagnos
sepsi
patient
diagnos
bronchiol
myopathi
interv
studi
drug
infus
end
apneafre
period
similar
group
geometr
mean
durat
hour
ci
hour
caffein
group
hour
ci
hour
placebo
group
ci
p
figur
frequenc
apnea
first
hour
similar
group
figur
avail
wwwjpedscom
caffein
group
significantli
longer
mean
median
length
stay
picustepdown
unit
mean
differ
hour
p
median
differ
hour
note
bed
avail
social
issu
may
impact
durat
mean
durat
apnea
episod
significantli
shorter
caffein
group
second
p
differ
limit
clinic
import
secondari
outcom
differ
group
tabl
ii
examin
resolut
apnea
subgroup
infant
halflif
caffein
prolong
clear
caffein
efficaci
subgroup
would
support
hypothesi
repeat
caffein
dose
rather
singl
larg
dose
gave
might
efficaci
subgroup
compris
patient
placebo
group
caffein
group
baselin
characterist
similar
caffein
placebo
group
data
shown
geometr
mean
durat
apneafre
period
hour
ci
hour
caffein
group
hour
ci
hour
placebo
group
ci
p
moreov
frequenc
apnea
first
hour
similar
group
figur
avail
www
jpedscom
analyz
risk
factor
associ
repeat
apnea
univari
multivari
model
tabl
iii
multivari
analysi
need
highflow
oxygen
posit
pressur
support
p
venou
po
mmhg
within
minut
present
emerg
center
ed
emerg
depart
pcr
polymeras
chain
reaction
baselin
characterist
similar
treatment
group
except
longer
durat
upper
respiratori
symptom
placebo
group
compar
caffein
group
mean
ae
day
vs
ae
day
p
signific
variabl
associ
higher
likelihood
apnea
admiss
record
spot
heart
rate
group
similar
time
except
hour
heart
rate
significantli
higher
caffein
group
compar
placebo
group
mean
increas
time
point
ci
p
patient
experienc
rhabdomyolysi
arrhythmia
cardiovascular
collaps
death
patient
apneaassoci
bronchiol
complet
resolut
apnea
within
hour
consist
recent
report
data
singl
dose
intraven
caffein
citrat
superior
normal
salin
outcom
measur
overal
treatment
group
subgroup
patient
age
day
caffein
would
expect
longer
halflif
current
avail
evid
caffein
use
bronchiolitisrel
apnea
observ
case
report
includ
patient
retrospect
studi
includ
patient
three
case
report
suggest
decreas
need
intub
mechan
ventil
caffein
administr
report
found
benefit
one
retrospect
studi
show
decreas
apnea
attack
hour
caffein
administr
anoth
found
decreas
need
intub
caffein
group
compar
noncaffein
group
third
report
inconclus
find
call
research
result
show
differ
frequenc
apnea
report
group
first
day
find
support
routin
use
caffein
treat
apnea
bronchiol
especi
light
report
seriou
side
effect
drug
believ
find
robust
appli
strict
enrol
criteria
random
blind
trial
patient
undergo
continu
cardiorespiratori
monitor
picu
stepdown
unit
median
length
stay
hour
nurs
patient
also
explor
previous
describ
risk
factor
apnea
addit
deem
relev
studi
patient
multivari
analysi
found
patient
staffwit
apnea
present
like
experi
apneic
episod
compar
patient
apnea
wit
home
report
previous
differ
signific
p
apnea
associ
venou
po
level
mmhg
obtain
within
minut
arriv
regardless
use
nonus
oxygen
therapi
need
highflow
oxygen
positivepressur
respiratori
support
studi
limit
power
find
signific
differ
time
end
studi
drug
infus
apneafre
period
limit
sampl
size
calcul
base
retrospect
survey
rather
apneafre
period
use
time
apneafre
period
admiss
unknown
moreov
sampl
size
estim
base
dichotom
outcom
apneafre
hour
wherea
clinic
trial
use
continu
outcom
time
end
studi
drug
infus
apneafre
period
although
found
benefit
caffein
sampl
size
estim
method
might
led
studi
underpow
identifi
possibl
measur
benefit
thu
larger
sampl
size
might
shown
pronounc
differ
treatment
group
time
achiev
apneafre
outcom
administr
higher
dose
caffein
use
present
studi
describ
previous
given
acut
respiratori
ill
associ
increas
metabol
rate
studi
popul
chose
instead
test
doubl
recommend
dose
apnea
prematur
mgkg
caffein
citrat
higher
dosag
apnea
bronchiol
use
previou
studi
studi
design
administ
singl
dose
caffein
rather
daili
dose
base
practic
previou
studi
find
high
proport
apnea
resolut
retrospect
data
collect
nonetheless
post
hoc
subgroup
analysi
show
superior
caffein
younger
infant
expect
halflif
caffein
hour
random
yield
entir
similar
group
shorter
durat
symptom
present
thu
possibl
sever
apnea
syndrom
group
treat
caffein
final
patient
studi
arm
requir
highflow
oxygen
may
provid
nearli
similar
support
continu
posit
airway
pressur
might
mask
apnea
attack
patient
n
